TW450815B - Local anesthetic pharmaceutical composition in gel form for external use - Google Patents
Local anesthetic pharmaceutical composition in gel form for external use Download PDFInfo
- Publication number
- TW450815B TW450815B TW086114947A TW86114947A TW450815B TW 450815 B TW450815 B TW 450815B TW 086114947 A TW086114947 A TW 086114947A TW 86114947 A TW86114947 A TW 86114947A TW 450815 B TW450815 B TW 450815B
- Authority
- TW
- Taiwan
- Prior art keywords
- weight
- content
- water
- lidocaine
- pharmaceutical composition
- Prior art date
Links
- 239000003589 local anesthetic agent Substances 0.000 title claims abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 24
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims abstract description 23
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 239000003655 absorption accelerator Substances 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 6
- 239000000194 fatty acid Substances 0.000 claims abstract description 6
- 229930195729 fatty acid Natural products 0.000 claims abstract description 6
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 2
- 230000000699 topical effect Effects 0.000 claims description 25
- 230000003444 anaesthetic effect Effects 0.000 claims description 20
- 238000011049 filling Methods 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 3
- 239000005642 Oleic acid Substances 0.000 claims description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 3
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 claims description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 3
- 241000736199 Paeonia Species 0.000 claims 1
- 235000006484 Paeonia officinalis Nutrition 0.000 claims 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 abstract description 38
- 229960004194 lidocaine Drugs 0.000 abstract description 38
- 229960001807 prilocaine Drugs 0.000 abstract description 7
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 abstract description 7
- 238000010521 absorption reaction Methods 0.000 description 21
- 239000004615 ingredient Substances 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 18
- 239000000243 solution Substances 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 238000002690 local anesthesia Methods 0.000 description 11
- 206010002091 Anaesthesia Diseases 0.000 description 10
- 230000037005 anaesthesia Effects 0.000 description 10
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 8
- 241000700198 Cavia Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- 230000002079 cooperative effect Effects 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 239000000701 coagulant Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 229960005015 local anesthetics Drugs 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000002691 topical anesthesia Methods 0.000 description 4
- 230000001133 acceleration Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- ACXGEQOZKSSXKV-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O.CCCCCCCC(O)=O ACXGEQOZKSSXKV-UHFFFAOYSA-N 0.000 description 3
- 235000015170 shellfish Nutrition 0.000 description 3
- 229940098465 tincture Drugs 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- WZSPWMATVLBWRS-UHFFFAOYSA-N 2-(diethylamino)-n-(2,6-dimethylphenyl)acetamide;n-(2-methylphenyl)-2-(propylamino)propanamide Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C.CCN(CC)CC(=O)NC1=C(C)C=CC=C1C WZSPWMATVLBWRS-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 125000004431 deuterium atom Chemical group 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 229960002446 octanoic acid Drugs 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- FGGKESDTDWWERY-UHFFFAOYSA-N 4-hydroxybutanimidamide Chemical compound NC(=N)CCCO FGGKESDTDWWERY-UHFFFAOYSA-N 0.000 description 1
- 102000040350 B family Human genes 0.000 description 1
- 108091072128 B family Proteins 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 241000269333 Caudata Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 244000018436 Coriandrum sativum Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000732800 Cymbidium Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 101100518501 Mus musculus Spp1 gene Proteins 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 230000000789 acetogenic effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- -1 hydroxypropyl Chemical group 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 229940048276 new coccine Drugs 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- UORPHRRDLIGMDN-SVMKZPJVSA-N octadec-2-enoic acid;(z)-octadec-9-enoic acid Chemical compound CCCCCCCCCCCCCCCC=CC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O UORPHRRDLIGMDN-SVMKZPJVSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000009304 pastoral farming Methods 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- GVKCHTBDSMQENH-UHFFFAOYSA-L phloxine B Chemical compound [Na+].[Na+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 GVKCHTBDSMQENH-UHFFFAOYSA-L 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000012731 ponceau 4R Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- BJPJNTKRKALCPP-UHFFFAOYSA-N prilocaine hydrochloride Chemical compound [Cl-].CCC[NH2+]C(C)C(=O)NC1=CC=CC=C1C BJPJNTKRKALCPP-UHFFFAOYSA-N 0.000 description 1
- 229960005094 prilocaine hydrochloride Drugs 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- DVGMLNVTRLVBSG-UHFFFAOYSA-N prop-2-enylideneiron Chemical class C(=C)C=[Fe] DVGMLNVTRLVBSG-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- AZJPTIGZZTZIDR-UHFFFAOYSA-L rose bengal Chemical compound [K+].[K+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 AZJPTIGZZTZIDR-UHFFFAOYSA-L 0.000 description 1
- STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- LKOVPWSSZFDYPG-WUKNDPDISA-N trans-octadec-2-enoic acid Chemical compound CCCCCCCCCCCCCCC\C=C\C(O)=O LKOVPWSSZFDYPG-WUKNDPDISA-N 0.000 description 1
- SWGJCIMEBVHMTA-UHFFFAOYSA-K trisodium;6-oxido-4-sulfo-5-[(4-sulfonatonaphthalen-1-yl)diazenyl]naphthalene-2-sulfonate Chemical compound [Na+].[Na+].[Na+].C1=CC=C2C(N=NC3=C4C(=CC(=CC4=CC=C3O)S([O-])(=O)=O)S([O-])(=O)=O)=CC=C(S([O-])(=O)=O)C2=C1 SWGJCIMEBVHMTA-UHFFFAOYSA-K 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- External Artificial Organs (AREA)
- Cyclones (AREA)
Description
450815 r Β7 經濟部中央棣準局員工消費合作社印裝 五、發明説明(I ) 本發明你闋於一種外用的局部麻醉爾。待別者,本發 明镍期於一種外用局部麻醉劑,其係便於利用施敷於* 赛之皮虜表面者;且為在經皮虜之吸收作用優異而速效 ,並且穩定性優良者β 背鲁持栴 經由皮》吸收型之外用局部麻醉剤之優黏在於例如給 藥時不須特別技術,不造成痛楚,可以麻醉宽廣之皮虜 表面而優於以皮磨或皮下注射之麻醉劑給蕖形式。所 以,經皮》吸收型之外用局部麻醉麵eta a相當的研 究(日本持開昭第57 -8 1 4 08 ,特開平4 -3 0 55 23,和特聞 平6-40347等號)5在«學機構之如B院中,外用局部麻 醉箝有時根嫌一種將有效麻醉劑成份輿例如油賫,乳箱 ,或«驪混合之方法而使用,製成一種B院或診所所配 製的局部麻醉劑,在給藥時用一種棰度氣密之樹脂膜如 聚鶴二《乙烯膜者予以密封,("001法";皮盧,34(2) ,237-242(1392)}。近來,一種阽紙形式之藥物已經開 發,且已上市供作β學用途。 然而,對習用藥局製繭已經發現如下之問題。亦即植 別的専利文獻之任何蕖局製_不足以成為透皮圾收且具 快速功效者。如用於轚院之局部麻醉劑,藥局製劑ffi製 成例如油膏,乳霜或凝黷形藥劑,逭些_局製_有一部 份穩定性不良,因此對如此之藥局製_需要在使用時製 備。此外,其他的_局製劑在使用上也不方便,而且需 (請先聞讀背面之注f項再填寫本頁) 本纸張尺度適用中國國家標準(CNS ) A4规格(210X297公釐} 45081 5 _ A7 B7 經濟部中央樣準局負工消费合作社印装 五、發明説明("·) 要長時間以顯現麻醉功效。再者,阽劑型_物不適合於 麻醉寞廣之皮着表面。雖然麻醉劑以高驀度(30至60%) 攆混,阽朗型藥物在透皮趿收和快速效上是有缺黏β 本發明採取上述觀點予以考at,其目的為提供一種外 用透皮吸收型局部麻醉劑,其在施敷和剝除時使用方便 ,可施用於寬赛之皮虜表面,且透皮吸收作用優異而速 效,穩定性優良。 本發明人等經致力研究以謀達成上項目的,已發現當 以S自利多卡因(Lidocaine丙按卡因(Prilocaine), 以及其在藥理上可被接受之鹽類,可被含於一種含水和 如乙酵輿異丙酵之較低醇類之混合溶液中,且可另含一 種透皮吸收加速黼而配製成一種藥局製劑,使可用作透 皮瞄收型局部麻醉劑,然後可能改善有效成分的透皮吸 收作用,並缩短顯現麻醉功效所爵之時間,而且含有上 述成分之蕖局製劑之棰定性餍異。因此已完成本發明。 換言之,本發明在於一種外用局部麻醉劑,包含a)— 選自利多卡因,丙胺卡因,和其在_理上可被接受之鹽 類之有效成分,b)—透皮吸收加速劑,c)乙酵及/或異 丙酵,以及d )水。 特定而言•含於本發明外用局部麻醉W中之b)透皮圾 收加速_較佳者包括脂肪酸,各具有8至18餹硪原子數 者,以及其在_理上可被接受之鹽類。在這些化合物中 .其為更合用者包活具有8個硪原子數之辛酸(羊酯酸) ~ 4 - -----------------------^ · If.. •i- /fv (請先聞讀背面之注意事碩再填寫本頁) 本紙張尺度適用中國圃家標準(CNS ) A4规格(2丨0X297公釐) A7 45081 5 ____ _B7__ 五、發明説明(4 ) ,具有18健硪原子數之十八烯酸(油酸),以及其在藥理 上可被接受之類。 待定而言,含於本發明外用局部麻醉繭中之d乙醇及 /或異丙酵.以及(1)水等,較佳者所表示乙酵及/或異 丙酵對水之重量比為在0.5至1.2之範圍所成之含量比。 本發明外用局部麻醉爾較好具有在6.0至8.5範園之pH值。 之形狀,本發明外用局部麻醉劑以例如一種凝匾 形蕖蘭而施用為佳β 本發明将詳述如後。 本發明外用局部麻醉割包含a)g自利多卡因,丙胺卡 因,及其在藥理上可被接受之鹽類之有效成份,b)透皮 圾收加速劑,c)乙酵及/或異丙酵,及d)水。上述a)至 d)之持定成份將接鑛説明如下。 al利多卡闵.诉粧卡闵和萁在藹理h?T埔格受之鹽親_ 利多卡因和丙胺卡因兩者為已知之局部麻醉劑。這些 化合物為易由化學合成而獲得。因此,化學合成之生成 物已知如上述者可以用作本發明之外用局部麻醉劑。7 般上,瘡些化合物為市面有售。因此.在本發明中也可 採用市售産品β本發明外用局部麻醉劑含有作為有效成 份者,單》為利多卡因或丙胺卡因,或將兩者混合。然 而,本發明外用局部麻醉劑可以含有一或多種利多卡因 和丙胺卡因在藥理上可被接受之鹽類,或取代其原化合 物,或對其添增。在藥理上可被接受之®特別包括例如刹 多卡因之《酸鹽,和丙胺卡因之鹽酸癢。 本纸張尺度適用中國困家梯举(CNS ) A4规格(210X297公釐} (請先閲讀背面之注f項再填寫本頁) 訂 經濟部中央梯準局wacx消费合作社印製 4508 1 5 A7 B7 五、發明説明(4 ) 在本發明外用局部麻醉劑中,S自利多卡因,丙胺卡 因,和其在藥理上可被接受之鹽類等有效成份之含量, 較佳為約2至12重量%,更佳者為5至10重量%,以第 局製Μ之總重量為準。然而,有效成份之含量随蕖劑之 形式或形狀,_劑之使用位置,和使用藥劑之方法而改 變。 h)播g I»收加速繭 經濟部中央樣準局具工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) 本發明外用局部麻醉_所含透皮吸收加速薄.並未待 別限定,而以吸收加速劑具有功能以加速利多卡因,丙 胺卡因,和其在_理上可被接受之鹽等而作為本發明外 用局部麻醉劑之有效成份等之透皮吸收作用,而且吸牧 加速繭為_理上可被接受之化合物等為條件。特定而言 ,用作透皮圾收加速劑之較佳者包括具有8至18値硪厣 子數之脂肪酸以及其在藥理上可被接受之鹽類。具有8 至18傾硝原子數之脂防酸包括例如,辛酸,癸酸,十四 烷酸,+六烷酸.硬勝酸,油酸(十八烯酸),亞油酸, 和亞麻酸。在這些化合物中.其用於本發明外用局部麻 醉劑之較诖者例如具有8傾硪原子數之辛酸,和具有18 傾硪原子數之油酸。這些脂肪酸在蕖理上可被接受之鹽 可以包括例如納鹽、鉀鹽、鈣鹽、鋁S、和鋅鹽。 本發明外用局部麻醉劑之透皮吸收加速劑之含景,當 採用具有8至18値硪原子數之脂昉酸或其在藥理上可被 接受之鹽用作透皮吸收加速爾時,其較佳含置為约1.0至 7.0重量%,更佳為2.0至4.0重量%,以藥局製劑结量 本紙張尺度適用中國圉家揉準(CNS ) A4规格(210X297公釐) A7 B7 450815 五、發明説明(厂) 為準,然而,透皮吸收加速_之含量随例如有效成份之 形式和含量而改變。 本發明外用局部麻醉劑包含乙醇及/或異丙醇和水, 作為在外用局部麻醉剤中所含之基本材料。乙醇及/或 異丙醇之比例,混合並包含作為本發明外用局部麻醉繭 之基本材料,較佳為在0.5至1.2之範圔内,且更佳為在 0.6至1.2之範圍内,以乙酵及/或異丙醇對水之重S比 表示。 乙醇及/或異丙酵和水之總含畺,亦邸在本發明外用 局部麻醉剤中基本材料之含量,較佳為約59至90重量% ,更佳為72至80重量%,以梁局製劑綰董為準,然而, 乙酵及/或異丙醇和水之總量例如隨有效成份和透皮吸 收加速劑之形式和含量而改變。 本發明外用局部麻醉劑含有上述a)至d)之特定成份。 然而,本發明外用局部麻醉劑,如有需要,S可含有通 常含於一般外用局部麻醉劑之任意成份,但以所含任意 成份在其不損及本發明效果之®圃内為條件。如此之任 意成份首先為例者為pH調節劑。基於透皮吸收作用之觀 鲇,本發明外用局部麻醉劑較佳之pH範圍約為B.0至8.5 之内,更佳為6.0至8.0之範園。為求調節pH值在上述較 佳範圍之内,本發明外用局部麻醉_可以含有一或多種 遘自包括鹽酸,乳酸,二異丙酵胺•和三乙酵按為例之 各種pH辋節蝌。pH諏節_之含量較佳為不多於8.0重量% 本紙浪尺度適用中困B家標準(CNS ) A4规格(210X297公釐) (锖先閱讀背面之注意事項再填寫本頁) 訂 經濟部中央樣準局貝工消費合作社印策 經濟部中央揉準局貝工消费合作社印袋 本紙張尺度逋用中國國家揉準(CNS > A4规格(210X2!»7公釐) 45081 5 at B7 五、發明说明u ) ,更佳為Q.05至5.5重畺%,以蕖局製劑之總量為準。 除了上述的PH調節_,可以包含於本發明外用局部麻 醉劑之任意成份,可為例如所含適當成份符合本發明外 用局部麻醉劑所可窸用用劑之各種形式或形狀者。用» 之形式或形狀,其在本發明外用局部麻醉劑之可應用者 ,包括例如,油裔、乳箱、鍰謬、掖劑、硬杳_、和期 劑等用然而,本發明外用局部麻醉薄之用爾形式或 形狀,較佳者為《腰形用繭β可用作任意成份而適於符 合各用嫌之各種形式或形狀者,可以在不損及本發明功 效之範画内被採用。 例如,當本發明外用局部麻辞劑為凝腰狀用劑而為本 發明之較佳者,其可用之任意成份包括.例如,多價酵 和高分乎量添加物,其如聚乙烯醇和纖維素衍生物。可 以用作聚乙烯基酵者較佳包括具有约為17㈣至2400之分 子量者β可用之鐵維素衍生物包括例如羥甲基鰌維素納 ,羥丙基繼維素,和羥丙基甲基纖維素》待定者,可用 之多價酵可以包括例如,甘油,丙二酵》1 ,3-丁二醇, 和聚乙烯基醇。 色料之如焦油染料者,可以加至本發明外用局部麻醉 劑,而不論用劑之形式或形狀,只依需要□因此,可能 得到一種有色的藥局製爾》特定者,可用之色料包括窠 事法規(Pharaaceutical Affairs Law)所載之有色材料 。此類有色物質包括如焦油染料,例如Aaaranth,新 Coccine, Phloxine B,和玫瑰 Bengale。 —--- (請先閲讀背面之注f項再填寫本頁) 訂 450815 A7 _______B7 五、發明説明(?) 製造本發明外用局部麻醉劑之方法.可以包jgg胃所 用以生産相當於本發明外用局部麻醉劑所廣用之各種形 式或形狀用_之方法。特定者,例如當本發明外用局部 麻醉Μ是以嫌腰用劑而生産者,其俱本發明外用局$麻 醉«所用較佳形式或形狀用薄,下述方法可為範例。然 而本發明並不受限於如下生産外用局部麻醉_之方法。 苜先,透皮吸收加速劑和苗自利多卡因,丙按卡因, 及其藥理上可被接受之鹽類之有效成份,被溶解於含有 乙酵及/或異丙酵和水之混合溶液中。或另改為,將有 效成份和透皮吸收加速劑分两各自溶解於乙酵及/或異 丙酵,或水,或其混合溶液,再將所得各溶液相互混合 。其後,以一藉将凝謬劑之如高分子量添加薄或多價酵 者溶解於乙酵及/或異丙酵,水,或其混合溶液而得之 溶液,與先前含有效成份及透皮吸收加速劑之溶液混合 • «得凝臛形用剤。如有霈要,在此方法之中,也可以 經濟部中央標準局員工消费合作社印簟 爾之法以香 剌 速序方可和 有 加程産,, 少 收合生要酵It 吸混述需價 皮 皮或上有多 對 透 / 在如, _ 份及,,料 醉 部序外際色 麻 一程此之, 部 或解 C度劑 局 /溶拌程節 用 及上檐拌調 外 份以和播值 明 成在熱或PH發 效。加 \ 如 本 有中如及其 之 份之例序, 得 部液行程扮 而 一溶進解成 述 入劑以溶意 所 加®I 可於任 上 先凝,,入。如 預至中中加料 梗 吸 充用 有 S 具而 上異 0 0 皮為 於一E ,醉 面麻 表部 ft局 I 皮用 9 之外· 麇明 寬發 於本 敷 施以 能所 且 〇 ,力 激收 本纸張尺度遥用中固國家揉丰(CNS > A4规格< 210X 297公釐) Α7 4508 1 β Β7 五、發明説明(ί ) (請先鬩讀背面之注意事項再填寫本頁) ,使其例如易施敷而能便於剝除。本發明外用局部麻醉劑 當使用時形成一塗層。因此,有效成份被妥為透皮吸收, 而且可在短期時間之内顯現麻醉效果。此外,本發明外 用局部麻醉劑當被配成藥局製劑時,其穩定性優異。 BL式服- 第1圖表示〇H值與透皮吸收利多卡因量(微克/公分2 ) 之醑葆,有關根據本發明所製含利多卡因之凝黷形用劑。 第2圔表示醇/水重置比與透皮吸收利多卡因量(微 克/公分2 )之鼸傺,有關根據本發明所裂含利多卡因 之凝驟形用爾。
奮施太發明之最佳H 本發明將參考實施例作更特定之説明如下。 實施例1至16 經濟部中央橾準局貝工消費合作社印製 外用局部麻醉剤,亦即表1所示利用各成份配製所産 利多卡因凝膠。換言之,一溶液(溶液A)産自以溶解或 懸浮和混合A組各持定成份,而一溶液(溶液B>産自加 熱並溶解或懸浮B組各待定成份。將上述所得溶液A加 至溶液B,曲而攢拌以獲得均勻混合物。此均勻混合物被 加入C組之各特定成份,曲以f«拌和勻化而産生凝膠形 用劑。其後,測量所得各凝謬形用劑之pH值,和酵(乙 醇及/或異丙酵)對所含之水之重畺比(如有需要,下文 將視為「酵/水重蛋比)。酵/水重量比見表1中間部 份,與pH值合併。 本紙張尺度適用中圃國家標準(CNS ) A4规格(2I0X297公釐)
450 8 1 S Α7Β7
Yt Ί)
D iv-;r 五 备明説明(?) ^TfJi明示,本案修正妓. 更原貧; 經濟部智慧財產局員工消資合作社印製 ^ ^ p 5§ S P _洚 \ w 卜> -豳 m \ 兴 Usll 两 W CT- o w > m m M蹂锘 羈 溶骆鸱頻报 兴摊丑IN驾 赘桝莼翌 择蝌 034 猫 細淫 a溫赍'^ 0 2 S o CO · • σ> o 〇〇 ο 1 1 Ο Μ Η-« · Ο CO cn 〇 · · CaJ o CO o <=> h-* μ-* t-* ο ο -3〇 o 03 · ♦ σ> CO A 1 1 Ρ ι ·—» σ> * ο tv? cn ο ^ C*i i—· PIP® ο ΰο o to 一— Ο ο 00 ο o --3 · « «4 >—to 1 ^ 1 IS5 办 ι — — O CS9 cn 〇 cn ω 卜 1 CO ο ο ο σ> ο Ca —— ί—♦ Ο CJ1 ο o σ> · • oo o a> 1 Ρ1 1 . Cki ι h-* oo 1 o co • » 办 Q办 ω j CO ο ο Ο CQ Ο 办 Ι-— ·-— Ν-- ο &0 Ο Cft P ♦ oo Cn c*> 1 Ρ 1 CO 也 — Ο ι O Cs9 1 * * ο ◦如 to — CO ο ο 1 ο οο ο C/l * 4-^ r· Ο Ο CO ο o -3 • oo «-* o 1 1 4^. »-* Η— f Ο tO 各 Ο办 CO ►— ι CO ο Ο 1 « » · Ο 00 ο σ> J-^ —Ο cn ο o -3 · σΐ ι r ι CO ►Ν — tvd ι O t〇 * I » » 〇> O CO ·-— 1 CO Ο Ο 1 ♦ * _ <=>00 0 — CO ο CO ο o 00 . - -J g σ> ι .° ι »— CO j o ro Ο ω — 1 CiJ Ο ρ Ο ΟΟ Ο CO CO CO Ο CO o CO * • OO o Γ3 Ρ i Ο 9) rf^· >-—ι O DO »1 · CO o办 C*J Η- 1 CO Ο Ο Ο ΟΟ ο CD CS ο -q ο o * cn -3 t〇 ι r ι ο e- <^1 O CO • 1 I cn o o ΙΟ »— 00 1 Ο Ο ο cn ο h-l· ο !-— ^ o o CO o r j-— OO 1 IP ρο CO ^-cn ι o 00 o o ^ ί— 1 F° 1 ? ο ο h-1 H-* -q oe O 03 4 P bo to 1 1 1 rfw ►— .°1 1 .°1 1 o o CO j to tn ◦ ο ο 1-^ -3 htk. CO cn to ^ P 1 ^ 1 ►Pfc. t—^ ^ ! Pi cn o CO ·— I 1 Ρ ο ο — 〇 O -J * • Csj 1 1 1 cn oo F° t PI O ◦ 1—* 1 cn to cn ο ο ο to CO CO ^ CO o cn , • CO to o 1 Γ1 ί ΓΟ CO σ> ι O to 1 · * 〇> o ^ CO h-t CO Ο Ο ι · * » Ο CO Ο CO to CO CO o to , • oo — 办 产丨1 «Λ CO to 1 O N> ΓΟ o C*> t-* j ο ο Ο CO ο 办 csi ►** cn -3 o , _ K** co cn ι r ι tn ' OS H-a ι o ro 1 * tn o o Κ-* ι Ο ΓΟ Ο 1 4 ο ο Ο CJ1 〇i tn CT> 〇 I-— -q , ► co tn 4S* IIP' CO — \ P id o, 办 — 合 co Ο ο Ο Ο 03 Μ 譜 鵁 室 (請先閲讀背面之注$項再填寫本頁) « 1^1 ί m HL ·
葙 銪 m ιΚ-Ν _ TO W Μ nn | „„訂----- - --- 本紙張尺度適用中國國家標準(CNS ) Μ規格(21 ΟΧ 297公釐) -11 - 4508 1 5 A7 B7 五、發明説明(I。) 一外用局部麻醉劑,亦邸利多卡因乳霜,其傜迄今所 用醱院_局製劑之相當品,是以表2所示使用之成份配 製作為比較例而産生。 換言之,表2所示A組成份被充份混合以播得一混合 物,然後以之與B組一成份均勻配合而産生利多卡因乳 霜^ Sonne基劑被用作B成份者是SONYBOD裂藥公司所製 乳化洗_之油膏基物質,含有單硬脂酸甘油酯,硬脂 醇,十六烷醇,輕質矽酐,鲸臘,丙二酵,聚氣乙烯十 六烷基W和鈍水等成份摻混。 (請先聞讀背面之注意事項再填寫本頁) 經濟部中央梯準局—工消费合作社印製 丟2 成 份 摻混董(重置% ) <為>利多卡因 10.0 甘油 30 . 0 <B>Sonne 基劑 60.0 麻醉效果(%) 33 吸收蛋(檝克/公分2) 30 本紙張尺度適用中國國家標準(CNS ) A4規格(2丨0X297公釐) 450815 A 7 B7 五、發明説明(") ϋ.發明·_外用局劑評估~ 在各實施例與比較例所得含利多卡因之外用局部麻醉 繭之藥局製爾分別對其麻醉效果,皮下吸收·和嫌定性 ,根嫌下列方法進行潮試而予評估。 (1)麻醉功效試驗 從Hartley型天竺竄(四周大,公)用剃剪(也用除毛«Π 除毛。藥局製劑(0.75克)被均勻施於各天竺鼠之背部 (9公分2,3公分X3公分)。在施敷後30分鐘剝去_ 局製_。在剝除藥局製_之後,在曾敷用_局製劑之背 部用曼陀鈴線刺激六次以觀察皮*有無孿编反應。未察 得孿縮反之次數用百分比代表輿總次數(六次 >之比。 此百分比被用為麻醉效果。麻醉功效試_是用兩隻天竺 鼠於每一藥局製剛而進行,取其平均值。
12J遽_JLJSL·收試 1L 經濟部中失標準局員工消费合作社印製 (諳先Μ讀背面之注意事項再填寫本頁) 在完成麻醉功效試驗之後,對所有天竺鼠在替施敷蕖 局製爾之背部,用涵浸遇酒精之棉花充份擦拭。隨後, 相當於中央部位之皮# (4公分2 , 2公分X2公分)被 試驗。含於受試皮纛中之局部麻醉Μ或其_ •根據高效 液態色脣分析法(HPLC法)測定而計算毎單位面積之吸收 置(微克/公分2 >。對毎一藥局製剤脚定兩隻已接受遇 上述試驗之天竺鼠而取其平均值。 在表1和2之最下方表示試驗結果如:(1)麻醉功效 試驗和(2)透皮吸收試驗。曲線鼷(第1圔)為對本發明 利多卡因凝醪用劑之pH值奧在天竺鼠中透皮吸收利多卡 ,-13- 本纸張尺度適用中a困家標準(CNS > Α4規格(2Ι0Χ 297公釐) 450815 Λ7 B7 五、發明説明(p) 因之量(微克/公分2 >間之阑你,獲自各實施例中各利 多卡因凝膠用劑之透皮吸收試驗之結果。相似者,一曲 線圖(第2 )得自對本發明利多卡因凝膠用劑之醇/水 重量比舆在天竺鼠中透皮圾收之利多卡因間之關傑。 從這些結果之所顳示,可以瞭解當獲自各實施例之利 多卡因凝腠用劑被施給至天竺鼠,輿在比較例中所得之 卡因乳霜比較,在施用後30分鐘所得利多卡因吸收之利 多卡因大,而麻醉效果相當優異。當造些结果與得自對 迄今用作醫院藥局製剤之利多卡因乳箱用ODT法之試驗結 果比較,此利多卡因乳霜具有與得自比較例者之組成大 致相間,亦即,事實上在施用乳箱之後箱約2小時始獾 充分之麻醉效果(皮*, 34(2),2 3 7 - 2 4 2 ( 1 9 3 2 ),可以確 定用本發明外用局部麻酔劑之狀況,其顯現麻醉功效所 需之時間極短。此外,関於獲自各實施例之利多卡因凝 膠用劑,顯示利多卡因凝膠用劑,其中酵/水重量比之 範圍為6至8. 5者,在透皮吸牧量和麻醉功效中均特別優 異》 經濟部中央揉隼局員工消費合作社印製 (請先閲讀背面之注意事項再填寫本頁) 利多卡因凝謬用劑,其為得自各實施例涉及基於使用 天竺鼠之試驗者,均棰便於使用,例如,當其被敷用和 剝除之時。所以本發明外用局部麻醉劑已被確認可被使 用於方便之情況。 f 棰宙袢試酴 將獲自實施例1和實施例5至10之利多卡因凝膠用劑 分別置於玻瑰小級中,緊予密封。随後貯於5 (TC之恒溫 楢内1個月。1偏月後,從恒溫槽取出所有的玻璃小瓶 -1 4 - 本紙張尺度適用中國國家標準(CNS ) A4規格(210XM7公釐) 經濟部中央標準局貝工消費合作杜印製 4508 1 5 A7 B7 五、發明説明(β) ,啓開以觀察各利多卡因凝朦用劑之外觀有無任何變化 (褪色和分離)。利多卡因之含置是用高效液態色層分析 法(HPLC法)對在50TC貯存1個月後之各利多卡因凝醪用 _鼉剷,以決定在50t貯存1傾月後之利多卡因含量對 _局製剤所配製者利多卡因含量之百分比。此百分比被 認為是利多卡因之剥餘比率(%)。評估結果如表3所示。 評估項目 實 施例 编號 1 5 6 7 8 9 10 外觀有無變化 補色 無 無 無 無 無 無 無 分離 無 無 無 無 無 無 無 卡因剩餘率) 98 98 98 99 100 98 100 如各結果所明示,察得並無外觀變化,亦邸,在50¾ 廉格條件下貯存1值月之後,各實施钶中所得利多卡因 凝膠用劑經觀察既未楢色亦無分_。在上述各實施例中 所得任何利多卡因凝謬用劑之狀況中,在配製時摻混於藥 局製劑中之利多卡因在上述條件下貯存後,以約〗〇〇% 之剩餘率留存於藥局製劑中,所以,認定本發明外用局 -15- 本紙張尺度適用中國國家榡準(CNS ) A4規格(210X297公釐) (請先聞讀背面之注意事項再填寫本頁) 訂 4 5 0 8 1 5 A7 B7 經濟部中央標準局負工消费合作社印衆 五、發明説明(·+) 部麻醉劑之穩定性亦極優異。 工1上2^1·用也 本發明外用局部麻醉_在敷用與剝除時便於使用,可 施用於寬廣之皮》表面,透皮吸收和速效性優異,而且 穩定性同樣優良。 (請先聞讀背面之注$項再填寫本頁) 本纸張尺度適用中酉國家搮準(CMS ) A4规格(210X297公釐)
Claims (1)
- 5, 1— 8 Q 5 4 A8B8C8D8 4正充修補 六、申請專利範圍 第86.14947號「,膠狀外用局部麻醉轚藥組合物」專 利案//·=;» A 。 -V-! '------ 1 (90年6月6日修正) Λ申請專利範圍: 1. 一種凝膠狀外用局部麻醉醫藥組合物,包含:(a) 一選自於利多卡因、丙胺卡因和其在藥學上可接受 鹽之有效成分;(b) —透皮吸收加速劑,選自於各 具有8至18個碳原子數之脂肪酸和其醫藥上可接 受鹽;(c)乙醇及/或異丙醇;及(d)水,其中乙醇 及/或異丙醇對水之含量比係在0.5至1.2以重量 表示之範圍內,pH値係在6.0至8.5之範圍內, 而有效成分的含量係2至12重量%,透皮吸收加速 劑的含量係1.0至7.0重量%,且相對於醫藥組合 物而言,乙醇及/或異丙醇和水的總含量係59至90 重量%。 2. 如申請專利範圍第1項之凝膠狀外用局部麻醉醫藥 組合物,其中脂肪酸係辛酸或油酸· <請先閲讀背面之注意事項再填寫本頁> --------訂---------線 經濟部智慧財產局員工消費合作杜印製 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP27081396 | 1996-10-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW450815B true TW450815B (en) | 2001-08-21 |
Family
ID=17491384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW086114947A TW450815B (en) | 1996-10-14 | 1997-10-13 | Local anesthetic pharmaceutical composition in gel form for external use |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US6429228B1 (zh) |
| EP (1) | EP0957906B1 (zh) |
| JP (1) | JP2001503035A (zh) |
| KR (1) | KR20000049125A (zh) |
| CN (1) | CN1135104C (zh) |
| AT (1) | ATE214599T1 (zh) |
| AU (1) | AU731946B2 (zh) |
| BG (1) | BG103325A (zh) |
| BR (1) | BR9711911A (zh) |
| CA (1) | CA2268535A1 (zh) |
| CZ (1) | CZ129899A3 (zh) |
| DE (1) | DE69711237T2 (zh) |
| DK (1) | DK0957906T3 (zh) |
| EA (1) | EA001611B1 (zh) |
| EE (1) | EE03743B1 (zh) |
| ES (1) | ES2173485T3 (zh) |
| HU (1) | HUP9904109A3 (zh) |
| ID (1) | ID21773A (zh) |
| IL (1) | IL129335A (zh) |
| LT (1) | LT4585B (zh) |
| MY (1) | MY118301A (zh) |
| NO (1) | NO991731L (zh) |
| NZ (1) | NZ335056A (zh) |
| PL (1) | PL332724A1 (zh) |
| PT (1) | PT957906E (zh) |
| RO (1) | RO120604B1 (zh) |
| SK (1) | SK284332B6 (zh) |
| TR (1) | TR199900814T2 (zh) |
| TW (1) | TW450815B (zh) |
| WO (1) | WO1998016212A1 (zh) |
| YU (1) | YU19399A (zh) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6528086B2 (en) * | 1999-09-28 | 2003-03-04 | Zars, Inc. | Methods and apparatus for drug delivery involving phase changing formulations |
| US20020006435A1 (en) * | 2000-01-27 | 2002-01-17 | Samuels Paul J. | Transdermal anesthetic and vasodilator composition and methods for topical administration |
| US6894078B2 (en) * | 2001-09-17 | 2005-05-17 | James G. Castillo | Alcohol based topical anesthetic formulation and method |
| US20040077593A1 (en) * | 2002-10-21 | 2004-04-22 | Marron Susan M. | Numbing gel for hair removal |
| US20040076671A1 (en) * | 2002-10-21 | 2004-04-22 | Aletha Tippett | Methods and compositions for topical wound treatment |
| JP4667369B2 (ja) * | 2003-03-21 | 2011-04-13 | ネックスメド ホールディングス インコーポレイテッド | 早漏を治療するための組成物および方法 |
| US20050014823A1 (en) * | 2003-07-17 | 2005-01-20 | Soderlund Patrick L. | Topical anesthetic composition and method of administration |
| EP1782831B1 (en) * | 2004-08-18 | 2011-10-19 | Medrx Co., Ltd. | External preparation |
| WO2007002304A2 (en) | 2005-06-22 | 2007-01-04 | Vnus Medical Technologies, Inc. | Methods and apparatus for introducing tumescent fluid to body tissue |
| US8920843B2 (en) * | 2007-11-07 | 2014-12-30 | Svip5 Llc | Slow release of organic salts of local anesthetics for pain relief |
| RU2497679C2 (ru) | 2008-10-02 | 2013-11-10 | Милан Инк. | Способ получения многослойного клеящегося ламинированного материала |
| DE102009007152A1 (de) * | 2009-02-02 | 2010-08-05 | Müller-Glewe, Gunter | Ultraschall-Gel |
| SG184072A1 (en) * | 2010-04-01 | 2012-10-30 | Pharmanest Ab | Bioadhesive compositions of local anaesthetics |
| CN102018696B (zh) * | 2010-11-22 | 2013-07-03 | 北京泰德制药股份有限公司 | 一种含有利多卡因或其药用盐的皮肤外用制剂 |
| EP2722040B1 (en) | 2011-06-20 | 2019-11-06 | Hisamitsu Pharmaceutical Co., Inc. | Lidocaine-containing patch |
| FR2983731B1 (fr) * | 2011-12-07 | 2014-04-25 | Univ Paris Descartes | Emulsions topiques a base de melanges eutectiques d'anesthesiques locaux et d'acide gras |
| CN103505791A (zh) * | 2012-06-28 | 2014-01-15 | 杨德普 | 透皮吸收局麻无痛注射穿刺酒精棉片 |
| CN103550675A (zh) * | 2013-09-04 | 2014-02-05 | 赵会霞 | 一种止痛贴 |
| KR102080860B1 (ko) * | 2018-04-11 | 2020-02-24 | 숭실대학교산학협력단 | 미세구조의 피부 흡수 증강제, 미세구조의 피부 흡수 증강제를 포함하는 국소 마취제, 및 미세구조의 피부 흡수 증강제를 포함하는 국소 마취제를 이용한 마취 방법 |
| CN110090197A (zh) * | 2019-04-19 | 2019-08-06 | 广州芮一生物科技有限公司 | 一种可成膜的麻醉面膜膏 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4954487A (en) * | 1979-01-08 | 1990-09-04 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions |
| CA1165240A (en) * | 1980-07-09 | 1984-04-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions |
| JPS57142913A (en) * | 1981-02-27 | 1982-09-03 | Nitto Electric Ind Co Ltd | Donor of physiologically active substance |
| US4748022A (en) | 1985-03-25 | 1988-05-31 | Busciglio John A | Topical composition |
| US4764381A (en) * | 1985-12-06 | 1988-08-16 | Key Pharmaceuticals, Inc. | Percutaneous penetration enhancer of oleic acid and 2-ethyl-1, 3-hexanediol |
| US5209724A (en) | 1988-04-11 | 1993-05-11 | Dhaliwal Avtar S | Composite anesthetic article and method of use |
| US5378730A (en) * | 1988-06-09 | 1995-01-03 | Alza Corporation | Permeation enhancer comprising ethanol and monoglycerides |
| JPH03501386A (ja) * | 1988-06-09 | 1991-03-28 | アルザ・コーポレーション | エタノール及びグリセロールモノオレエートを含む透過促進剤 |
| JPH0755167B2 (ja) * | 1988-09-21 | 1995-06-14 | 松下電器産業株式会社 | 移動体 |
| US4892737A (en) * | 1988-09-22 | 1990-01-09 | University Of Florida | Composition and method for enhancing permeability of topical drugs |
| GB9101986D0 (en) | 1991-01-30 | 1991-03-13 | Smith & Nephew | Pharmaceutical compositions |
| JPH04261119A (ja) * | 1991-02-13 | 1992-09-17 | Lintec Corp | 経皮吸収型貼付剤 |
| JP3115625B2 (ja) * | 1991-03-30 | 2000-12-11 | 帝國製薬株式会社 | リドカイン含有外用貼付剤 |
| JP2775203B2 (ja) | 1991-05-11 | 1998-07-16 | 久光製薬株式会社 | 吸収促進組成物 |
| JPH0640947A (ja) | 1992-07-28 | 1994-02-15 | T T S Gijutsu Kenkyusho:Kk | 経皮吸収製剤用組成物および経皮吸収製剤 |
| JPH0694891A (ja) | 1992-09-10 | 1994-04-08 | Kawasaki Heavy Ind Ltd | 使用済燃料貯蔵・輸送容器 |
| JPH08286701A (ja) | 1995-04-11 | 1996-11-01 | Nissan Motor Co Ltd | 複数ロボット制御方法およびシステム |
-
1997
- 1997-10-06 PT PT97942259T patent/PT957906E/pt unknown
- 1997-10-06 ES ES97942259T patent/ES2173485T3/es not_active Expired - Lifetime
- 1997-10-06 KR KR1019990703209A patent/KR20000049125A/ko not_active Ceased
- 1997-10-06 SK SK482-99A patent/SK284332B6/sk unknown
- 1997-10-06 CN CNB97180639XA patent/CN1135104C/zh not_active Expired - Fee Related
- 1997-10-06 AU AU43996/97A patent/AU731946B2/en not_active Ceased
- 1997-10-06 EP EP97942259A patent/EP0957906B1/en not_active Expired - Lifetime
- 1997-10-06 ID IDW990176A patent/ID21773A/id unknown
- 1997-10-06 BR BR9711911-3A patent/BR9711911A/pt not_active IP Right Cessation
- 1997-10-06 US US09/284,124 patent/US6429228B1/en not_active Expired - Fee Related
- 1997-10-06 AT AT97942259T patent/ATE214599T1/de not_active IP Right Cessation
- 1997-10-06 PL PL97332724A patent/PL332724A1/xx unknown
- 1997-10-06 YU YU19399A patent/YU19399A/sh unknown
- 1997-10-06 TR TR1999/00814T patent/TR199900814T2/xx unknown
- 1997-10-06 IL IL12933597A patent/IL129335A/en not_active IP Right Cessation
- 1997-10-06 EA EA199900376A patent/EA001611B1/ru not_active IP Right Cessation
- 1997-10-06 RO RO99-00416A patent/RO120604B1/ro unknown
- 1997-10-06 JP JP10518171A patent/JP2001503035A/ja not_active Ceased
- 1997-10-06 DE DE69711237T patent/DE69711237T2/de not_active Expired - Lifetime
- 1997-10-06 HU HU9904109A patent/HUP9904109A3/hu unknown
- 1997-10-06 WO PCT/JP1997/003567 patent/WO1998016212A1/en not_active Ceased
- 1997-10-06 CA CA002268535A patent/CA2268535A1/en not_active Abandoned
- 1997-10-06 CZ CZ991298A patent/CZ129899A3/cs unknown
- 1997-10-06 EE EEP199900144A patent/EE03743B1/xx not_active IP Right Cessation
- 1997-10-06 DK DK97942259T patent/DK0957906T3/da active
- 1997-10-06 NZ NZ335056A patent/NZ335056A/xx unknown
- 1997-10-10 MY MYPI97004764A patent/MY118301A/en unknown
- 1997-10-13 TW TW086114947A patent/TW450815B/zh not_active IP Right Cessation
-
1999
- 1999-04-13 NO NO991731A patent/NO991731L/no not_active Application Discontinuation
- 1999-04-13 BG BG103325A patent/BG103325A/xx unknown
- 1999-04-13 LT LT99-036A patent/LT4585B/lt not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW450815B (en) | Local anesthetic pharmaceutical composition in gel form for external use | |
| US20180256495A1 (en) | External preparation comprising fatty acid salt or benzoic acid salt of basic pharmacologically active component, and method for production thereof | |
| JPWO2009066457A1 (ja) | 脂肪酸系イオン液体を有効成分とする外用剤組成物 | |
| US4440778A (en) | Anti-inflammatory analgesic cataplasm and process for producing the same | |
| JPS5855417A (ja) | 医薬組成物 | |
| JPH05105628A (ja) | 外用消炎鎮痛剤 | |
| CN115337289A (zh) | 含有右酮洛芬或其药用盐的凝胶贴膏基质及其制备方法 | |
| JP4541686B2 (ja) | 非ステロイド系消炎鎮痛剤を含有するテープ剤 | |
| PT100638B (pt) | Metodo para evitar e tratar a alopecia induzida por quimioterapia | |
| PT91637B (pt) | Processo para a preparacao de uma matriz auto-adesiva para administracao de um principio activo por via percutanea, contendo um copolimero de etileno e de acetato de vinilo | |
| JPH03275621A (ja) | 外部適用用の製剤及びその製造方法 | |
| JPWO1999018955A1 (ja) | 経皮吸収型製剤 | |
| CN101138560B (zh) | 呋喃西林凝胶剂及其制备方法 | |
| WO1999018955A1 (fr) | Preparation absorbable par voie percutanee | |
| TW201223528A (en) | Transdermal absorption preparation | |
| TW411273B (en) | Pharmaceutical composition for treating and preventing postmenopausal cardiovascular disease in women | |
| JP2000336028A (ja) | カプセル剤 | |
| JP5720240B2 (ja) | 外用剤 | |
| JPS59130811A (ja) | 粘着性貼付製剤用膏体 | |
| CN105769751B (zh) | 一种埃普利诺菌素乳剂凝胶及其制备方法 | |
| CN111867574A (zh) | 含有双氯芬酸的乳化凝胶组合物 | |
| JPH0477425A (ja) | インドメタシン含有貼付剤 | |
| JPS6053150A (ja) | ゴム系粘着性膏体 | |
| TW200418516A (en) | Droplet dispersed ointment | |
| TW386033B (en) | A skin permeant pharmaceutical compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GD4A | Issue of patent certificate for granted invention patent | ||
| MM4A | Annulment or lapse of patent due to non-payment of fees |